Table 3.

Initiation of CNS-Active Medication and Risk of Fall-Related Injury

CNS Medication Use	Primary Analysis					Sensitivity Analysis†,‡
	Person-Years	Fall-Related Injury	Fall-Related Injury Rate (per 100 person-years)	Adjusted* ,†
				HR	95% CI	HR	95% CI
No current use	13,902	503	3.6	1.00	Reference	1.00	Reference
Prevalent use	1,160	72	6.2	1.52	(1.18–1.97)	1.46	(1.04–2.05)
New initiation	468	49	10.5	2.81	(2.09–3.78)	2.68	(1.78–4.04)
According to SDD
<1	184	17	9.2	2.47	(1.52–4.01)	2.15	(1.06–4.36)
1–<2	160	24	15.0	4.04	(2.67–6.10)	3.80	(2.16–6.68)
≥2	125	8	6.4	1.75	(0.87–3.52)	1.96	(0.80–4.77)

Note: SDD = standardized daily dose; HR = hazard ratio; CI = confidence interval.

*Results for primary outcome of fall-related injury resulting in ED or outpatient visit or hospitalization.

^†Adjusted for age, sex, ACT study cohort, and time varying measures of: body mass index, self-rated health, hypertension, diabetes, stroke, urinary incontinence, osteoarthritis, coronary artery disease, congestive heart failure, Parkinson’s disease, gait speed, depressive symptoms, impaired cognition, and poor vision.

^‡Adjusted HR for the outcome of fall-related injury resulting in ED visit or hospitalization.